Clinical Trial

Incretin Action in Physiology and Diabetes

Study Description

Incretin Action in Physiology and Diabetes

This project is designed to advance understanding of the incretin effect in health and disease. This system of gut-islet linkage is essential for normal glucose tolerance, impaired in T2DM, and amenable to therapeutic intervention. However, there are important gaps in understanding incretin function that limit application of this system; this project will address several of these. A secondary, but critical aspect of this research is focus on inter-individual variation in the physiology of the incretin system. This is a novel direction for research in this field and is critical to advancing the concept of individualized medical care in diabetes by establishing whether there is a physiologic basis for predicting the existence of responders and non-responders to incretin therapies. Currently, we have described only Aim 1 from this grant in this protocol registration. While Aim 2 and 3 are described in the grant, Aim 1 will be conducted first and the results from this Aim and / or the publication of other results in the field may affect the approach to Aims 2 and 3.

Location

Locations Selected Location

Methods

Pharmaceutical medication involved Pharmaceutical medication involved
Patients and healthy individuals accepted Patients and healthy individuals accepted

Drug - GIP infusion

after establishing a hyperglycemic clamp (target: 125 mg/dL) GIP will be infused

Drug - GLP-1 infusion

after establishing a hyperglycemic clamp (target: 125 mg/dL) GLP-1 will be infused

Drug - Ex-9 infusion

Ex-9 infusion will be initiated at start of hyperglycemic clamp (target: 125 mg/dL)

Additional Information

Official Study Title

Incretin Action in Physiology and Diabetes

Clinical Trial ID

NCT02550548

ParticipAid ID

zbqDka